Actuate Therapeutics, Inc. ACTU 深 滬
等待開盤 04-18 09:30:00 美东时间
2.13
-0.020
-0.93%
華盛通- 最 高2.23
- 今 開2.23
- 成交量 3.77万股
- 最 低 2.1001
- 昨 收 2.15
- 總市值 5050.22万
- 52周最高 11.99
- 市盈率 靜 --
- 換手率 0.16%
- 52周最低 1.58
- 委 比 -46.63%
- 總股本 2370.99万
- 歷史最高 11.99
- 量 比 0.35
- 振 幅 6.04%
- 歷史最低 1.58
- 每 手 1
- 風險率 2.17%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Did Actuate Therapeutics (ACTU) Stock Jump Over 14% After Hours?
Actuate Therapeutics shares surged 14.41% after-hours after Nature Medicine published Phase 2 data showing elraglusib plus chemotherapy improved overall survival in metastatic pancreatic cancer.
04-16 15:34
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers BNB Plus (NASDAQ:BNBX) stock moved upwards by 12.7% to $0.65 during Tu...
04-15 05:05
美股大行评级 | 大摩上调哔哩哔哩目标价从25美元升至31美元；大砍近50%！汇丰下调耐克目标价从90美元降至48美元
今日重点评级关注：HC Wainwright & Co.：维持Solaris Resources"买入"评级，目标价从16美元升至18美元；Leerink Partners：维持Spyre Therapeutics"跑赢大市"评级，目标价从49美元升至106美元
04-14 10:44
Netflix To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, including upgrades and downgrades, on our analyst ratings page.
04-13 20:45
HC Wainwright & Co. Maintains Buy on Actuate Therapeutics, Lowers Price Target to $15
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Actuate Therapeutics (NASDAQ:ACTU) with a Buy and lowers the price target from $20 to $15.
04-13 18:57
Actuate Therapeutics Launches Strategic Research Initiative To Combine Elraglusib With RAS Inhibitors
The combination strategy is designed to simultaneously block proliferative signaling through RAS inhibition and disrupt tumor survival pathways via elraglusib's GSK-3β inhibition, potentially enhancing apoptotic
03-09 20:48
Actuate Therapeutics Intends To Initiate Phase 1/2 Clinical Program To Evaluate Oral Tablet Dosage Form Of Elraglusib In Patients With Advanced Cancer
Actuate Therapeutics, Inc. (NASDAQ: ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the
01-21 21:51
Actuate Announces Results From Phase 1 Portion Of Phase 1/2 Clinical Study Evaluating Elraglusib As Monotherapy Or In Combination With Irinotecan, Irinotecan Plus Temozolomide, Or With Cyclophosphamide Plus Topotecan In Pediatric Patients With Refractory Malignancies
Two Complete Metabolic Responses (CMRs) observed in patients with relapsed/refractory metastatic Ewing sarcoma and one Complete Response (CR) observed in a patient with relapsed/refractory metastatic
01-06 21:47
Actuate Therapeutics Announces Publication Of New Data In Clinical Cancer Research From A Phase II Study; Reports Phase II Results Of Elraglusib With Platinum Chemotherapy Shows Median Survival Of 18.6 Months In Refractory Salivary Gland Cancer
Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years.Results suggest that nuclear GSK-3β expression may help identify patientsmost likely to respond to treatment of a
2025-12-15 21:49
Actuate Therapeutics Signs $100M Sales Agreement
An update from Actuate Therapeutics, Inc. ( ($ACTU) ) is now available. On Nove...
2025-11-29 06:48
